Research programme: kinase inhibitors - Gilead Sciences

Drug Profile

Research programme: kinase inhibitors - Gilead Sciences

Alternative Names: ASK1i; TANK Binding Kinase 1 and and I-Kappa B Kinase Epsilon inhibitor - Gilead Sciences; TBK1/IKBKE inhibitor - Gilead sciences

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences
  • Class Antineoplastics; Antirheumatics; Small molecules
  • Mechanism of Action I-kappa B kinase inhibitors; MAP kinase kinase kinase inhibitors; TBK1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Rheumatoid arthritis

Most Recent Events

  • 01 May 2017 Pharmacodynamics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AARC-2017)
  • 01 Apr 2017 Preclinical trials in Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top